Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
نویسندگان
چکیده
1 Neurocritical Care Unit, Centre Hospitalier Universitaire Sud Réunion, Saint-Pierre, France, 2 Department of Neurosurgery, Centre Hospitalier Universitaire Sud Réunion, Saint-Pierre, France, 3 INSERM, UMR 1188 Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), plateforme CYROI, Sainte Clotilde, France, 4 Centre d’Études Périnatales de l’Océan Indien (CEPOI) – EA 7388, Centre Hospitalier Universitaire Sud Réunion, Saint-Pierre, France, 5 Pediatric and neonatal intensive care unit, Centre Hospitalier Universitaire Sud Réunion, Saint-Pierre, France
منابع مشابه
Management of immune thrombocytopenia--something old, something new.
For most of my career, the management of immune thrombocytopenia has evolved from clinical experience rather than clinical evidence. When I was a medical student at Ohio State University in 1960, my mentors were shifting their initial treatment for immune thrombocytopenia from splenectomy to the recently available glucocorticoids.1 Over the next 40 years, although multiple other treatments were...
متن کاملSpotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. In approximately one-third of cases, the duration of thrombocytopenia will extend beyond 12 months consistent with a diagnosis of chronic ITP. Minor bleeding manifestations are common in chronic ITP while severe or life-threatening bleeding complications are uncommon. Moreover, spontaneou...
متن کاملRomiplostim-induced myelofibrosis.
A 55-year-old woman with chronic refractory idiopathic thrombocytopenic purpura (ITP) presented with gum bleeding for 1 day. Over the course of several years, she had failed, or became resistant to, multiple treatments including glucocorticoids, intravenous immunoglobulin, splenectomy, rituximab, and, recently, a 9-month course of weekly romiplostim with moderate compliance. A complete blood co...
متن کاملLong-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
Inhibition of platelet production and mediated by antiplatelet antibodies is a well-known mechanism causing low platelet counts in immune thrombocytopenia (ITP). Use of thrombopoietin receptor agonists increases platelet counts and decreases the risk of bleeding in patients with ITP. Two such thrombopoietin receptor agonists, romiplostim and eltrombopag, are approved by the US Food and Drug Adm...
متن کاملTotal remission of severe immune thrombocytopenia after short term treatment with romiplostim
Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and it is now accepted that the disorder is due to increased platelet destruction and decreased platelet production from megakary-ocytes. Thrombopoietin (TPO)-receptor agonists (ro...
متن کامل